bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung

Key Takeaway: bioAffinity Technologies has reported its first quarter results for 2026, highlighting the ongoing adoption and clinical usage of its CyPath® Lung product. The company is focused on expanding its market presence and enhancing the capabilities of its offerings. Specific financial details and growth metrics were not disclosed in the article.